For Enquiries: CALL +91-9774064470

Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

This article was reported and written in a collaboration with ProPublica, the nonprofit investigative journalism organization.An artificial intelligence start-up founded by three insiders at Memorial Sloan Kettering Cancer Center debuted with great fanfare in February, with $25 million in venture capital and the promise that it might one day transform how cancer is diagnosed.The company, Paige.AI, is one in a burgeoning field of start-ups that are applying artificial intelligence to health care, yet it has an advantage over many competitors: The company has an exclusive deal to use the cancer center’s vast archive of 25 million patient tissue slides, along with decades of work by its world-renowned…

Continue Reading

Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals

Board of Directors ■ Aura Biosciences* (cancer startup) ■ Bristol-Myers Squibb ■ Foghorn Therapeutics (cancer startup) ■ Grail* (cancer testing startup) ■ Infinity Pharmaceuticals* (cancer startup) ■ Varian Medical Systems (radiation equipment) Scientific or Clinical Advisory Board ■ ApoGen Biotechnologies (cancer startup) ■ Aura Biosciences (cancer startup) ■ Grail (cancer testing startup) ■ Juno Therapeutics* ■ Northern Biologics (cancer startup) ■ Paige.AI (pathology startup) ■ Peptomyc* (cancer startup) ■ PMV Pharmaceuticals (cancer startup) ■ Seragon Pharmaceuticals* (breast cancer) Founder or Co-Founder ■ Mosaic Biomedicals* ■ Tango Therapeutics (cancer startup) Paid Consultant ■ AstraZeneca* ■ Eli Lilly* ■ Novartis* ■ Roche/Genentech*

Continue Reading